Improved
5878 HealthChanged
3669 LivesSaved
3464 Lives0 lives impacted in the last 24 hrs Learn More
MonkeyBusiness Images/PhotoSpin
The FDA issued a safety advisory asking surgeons to stop using power morcellators during uterine surgery in April, 2014, as the practice presents a risk spreading cancerous tissue. EmpowHER reported on this situation at that time.
Since then, many hospitals put moratoriums on the tool, and some insurers stopped covering its use. Johnson & Johnson issued a voluntary recall of their power morcellators due to the cancer risk.
However, in spite of the FDA warning, many doctors are still using power morcellators.
Laparoscopic techniques make it possible to perform uterine surgery through very small incisions. This allows for less blood loss and scarring, and a faster recovery.
Using a power morcellator, larger tissues are cut into smaller ones that are then pulled through the small incisions. In April, 2014 the FDA estimated this surgery was performed roughly 50,000 times a year.
This procedure creates a substantial and hidden risk to the patient, according to the Jewish Journal. Women with undetected cancers are at the greatest risk.
About 1 in 350 women have cancerous tissues in or around their uterine fibroids. When the morcellator cuts up the fibroids, it also cuts up the cancerous tissues, and can leave some behind to migrate to other areas, where they can re-seed new cancerous tumors.
The FDA warning sharply divided doctors.
Robert Graebe MD, the Department of Obstetrics and Gynecology chairman at New Jersey’s Monmouth Medical Center, first thought the FDA had overreached but now agrees with the safety advisory. He thinks power morcellators should be shelved until proven safe.
He told Wall Street Journal (WSJ), "People want to fight back, but it's not putting patients' safety first. It's not worth playing Russian roulette with the patient."
Others believe that the unknown cancer risks are overblown and that patient treatment has no room for government interference.
Add a CommentComments
There are no comments yet. Be the first one and get the conversation started!